The &quot;Sweet Spot&quot; in Type 2 Diabetes Management

July 24th 2025

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Both metformin and GLP-1 RAs have been studies for their neuroprotective effects; this study is the first head-to-head investigation and supports further research.

New Guidelines Recommend Preconception Screening in Diabetes, Universal Testing for Primary Aldosteronism

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

July 16th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.

August 30th 2023

GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

July 9th 2025

Body Fat Percentage Outperforms BMI in Predicting Mortality Risk in Young Adults: New Findings

GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.

BF% outperforms BMI in Predicting Morality risk in young adults: New Findings / image courtesy of University of Florida

GLP-1 RAs vs Metformin Significantly Reduce Risk of Dementia in Adults with Type 2 Diabetes

Body fat percentage and waist circumference were both significantly associated with 15-year all-cause mortality while BMI had no significant association.

Related Content

July 24th 2025

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Both metformin and GLP-1 RAs have been studies for their neuroprotective effects; this study is the first head-to-head investigation and supports further research.

New Guidelines Recommend Preconception Screening in Diabetes, Universal Testing for Primary Aldosteronism

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

July 16th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.

August 30th 2023

GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

July 9th 2025

Body Fat Percentage Outperforms BMI in Predicting Mortality Risk in Young Adults: New Findings

GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.